Transgenomic Inc. Launches Next Generation SURVEYOR(R) Mutation Detection Kits For Fluorescent Capillary Electrophoresis

Transgenomic, Inc. (Nasdaq: TBIO) announced today that it is launching its next generation SURVEYOR Mutation Detection Kits for universal primer fluorescent capillary electrophoresis. The kits detect mismatch mutations in DNA that has been PCR amplified using two fluorescent primers and digested with SURVEYOR Nuclease. This then allows highly sensitive mutation detection on Applied Biosystems DNA sequencing instruments. It will be a key tool for scientists needing high-throughput analysis of genetic variation, even for those variations present at very low levels such as somatic mutations linked to cancer and its treatment.

Introduced by Transgenomic in 2004, SURVEYOR Nuclease is a proprietary mismatch-specific endonuclease that efficiently detects any mismatches in double-stranded DNA and cleaves at the site of DNA mutations. It identifies all base substitutions, insertions and deletions and can detect multiple mutations in a single fragment, in individual or even pooled PCR samples. SURVEYOR Nuclease's effectiveness in disease specific mutation discovery has been well documented in many peer-reviewed publications over the past two years.

In announcing the product launch, Craig Tuttle, Transgenomic, Inc. CEO, commented that, "We are excited to extend the SURVEYOR Mutation Detection Kit product line and provide such an important research tool to detect mutations that sequencing cannot find, or finds difficult to reveal. SURVEYOR also saves researchers time and money with its increased precision. SURVEYOR Endonuclease is an important expansion of Transgenomic's mutation detection product portfolio which is exemplified by our WAVE(R) System platforms and our emerging CLIA and GLP Clinical Reference Laboratory and Genomic Analysis and Research Services."

To find out more about SURVEYOR Nuclease, go to http://www.transgenomic.com

About Transgenomic: A decade of discovery 1997 - 2007

Transgenomic is a global biotechnology company that provides unique systems, products, discovery and laboratory testing services to the academic and medical research, clinical and pharmaceutical markets for automated high sensitivity genetic variation and mutation analysis in the fields of pharmacogenomics and personalized medicine. This is accomplished through their offerings of Wave(TM) DHPLC systems, reagents, consumables and assay kits, automated cytogenetics systems and Transgenomic Discovery and CLIA Lab Services. To date there have been over 1,200 Wave systems installed in over 600 customer sites in over 35 countries and approximately 1,500 publications utilizing Transgenomic products or services. Transgenomic Discovery and Lab Services utilize their technology and expertise to provide a menu of mutation scanning tests for over 700 cancer-associated genes and more than 60 validated diagnostic tests to meet the needs of pharmaceutical and biotech companies, research and clinical laboratories, physicians and patients. For more information about the innovative systems, products and services offered by Transgenomic, please visit: http://www.transgenomic.com.

Transgenomic Cautionary Statements

Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

Transgenomic, Inc.
http://www.transgenomic.com